NASDAQ:INNT - Innovate Biopharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.03 -0.12 (-2.33 %)
(As of 10/19/2018 04:00 PM ET)
Previous Close$5.03
Today's Range$4.92 - $5.29
52-Week Range$3.43 - $50.50
Volume241,474 shs
Average Volume573,059 shs
Market Capitalization$133.82 million
P/E RatioN/A
Dividend YieldN/A
Beta-14.87
Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase 2b clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase 1 clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease. In addition, the company holds global rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase 3 clinical trial. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.

Receive INNT News and Ratings via Email

Sign-up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INNT
CUSIPN/A
Phone919-275-1933

Debt

Debt-to-Equity RatioN/A
Current Ratio1.46
Quick Ratio1.46

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.88 million
Price / Sales69.51
Cash FlowN/A
Price / CashN/A
Book Value($1.37) per share
Price / Book-3.67

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-7,920,000.00
Net MarginsN/A
Return on Equity-1,098.06%
Return on Assets-304.41%

Miscellaneous

Employees5
Outstanding Shares25,980,000
Market Cap$133.82 million

Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions

What is Innovate Biopharmaceuticals' stock symbol?

Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."

How were Innovate Biopharmaceuticals' earnings last quarter?

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) released its quarterly earnings results on Wednesday, August, 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.21) by $0.05. View Innovate Biopharmaceuticals' Earnings History.

When is Innovate Biopharmaceuticals' next earnings date?

Innovate Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 21st 2018. View Earnings Estimates for Innovate Biopharmaceuticals.

What price target have analysts set for INNT?

2 Wall Street analysts have issued 12-month price objectives for Innovate Biopharmaceuticals' shares. Their predictions range from $35.00 to $35.00. On average, they anticipate Innovate Biopharmaceuticals' share price to reach $35.00 in the next year. This suggests a possible upside of 595.8% from the stock's current price. View Analyst Price Targets for Innovate Biopharmaceuticals.

What is the consensus analysts' recommendation for Innovate Biopharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovate Biopharmaceuticals.

What are Wall Street analysts saying about Innovate Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Innovate Biopharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Innovate Biopharmaceuticals, Inc. is a clinical stage biotechnology company. It focused on developing novel medicines for autoimmune/ inflammatory disease. The company's pipeline includes drug candidates for celiac disease, an unmet need, and ulcerative colitis. Its products includes INN-202 for the treatment of Celiac Disease with fast track designation, INN-108 for Inflammatory Bowel Disorders, mild to moderate Ulcerative Colitis and a GI orphan disease in a convenient liquid formulation, INN-329 for Magnetic Resonance Cholangiopancreatography which are in clinical stages. Innovate Biopharmaceuticals Inc., formerly known as Monster Digital, Inc., is based in SIMI VALLEY, United States. " (10/17/2018)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We utilize a composite discounted cash flow (DCF)-based analysis methodology, which ascribes $750M to INN-202 in celiac disease (70% probability of success based on positive Phase 2b data and 15% discount rate), $400M to INN-108 in ulcerative colitis (65% probability of success and 12% discount rate), and $130M to another formulation of larazotide, designated INN-217, for treatment of NASH (35% probability of success, along with a 15% discount rate)." (8/1/2018)

Who are some of Innovate Biopharmaceuticals' key competitors?

Who are Innovate Biopharmaceuticals' key executives?

Innovate Biopharmaceuticals' management team includes the folowing people:
  • Mr. Sandeep Laumas M.D., Exec. Chairman (Age 49)
  • Dr. Christopher P. Prior, CEO & Director (Age 65)
  • Mr. Jay P. Madan M.S., Pres, Chief Bus. Officer, Interim Principal Financial & Accounting Officer and Director (Age 52)
  • Dr. June S. Almenoff, COO & Chief Medical Officer (Age 61)
  • Jerry Gardner M.D., Head of Clinical Strategy

Who are Innovate Biopharmaceuticals' major shareholders?

Innovate Biopharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.08%). Company insiders that own Innovate Biopharmaceuticals stock include Christopher P Prior, June Sherie Almenoff and Sandeep Laumas. View Institutional Ownership Trends for Innovate Biopharmaceuticals.

Which institutional investors are buying Innovate Biopharmaceuticals stock?

INNT stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have bought Innovate Biopharmaceuticals stock in the last two years include Christopher P Prior, June Sherie Almenoff and Sandeep Laumas. View Insider Buying and Selling for Innovate Biopharmaceuticals.

How do I buy shares of Innovate Biopharmaceuticals?

Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innovate Biopharmaceuticals' stock price today?

One share of INNT stock can currently be purchased for approximately $5.03.

How big of a company is Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals has a market capitalization of $133.82 million and generates $1.88 million in revenue each year. Innovate Biopharmaceuticals employs 5 workers across the globe.

What is Innovate Biopharmaceuticals' official website?

The official website for Innovate Biopharmaceuticals is http://www.innovatebiopharma.co.

How can I contact Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]


MarketBeat Community Rating for Innovate Biopharmaceuticals (NASDAQ INNT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  211
MarketBeat's community ratings are surveys of what our community members think about Innovate Biopharmaceuticals and other stocks. Vote "Outperform" if you believe INNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2018 by MarketBeat.com Staff

Featured Article: Do You Need a Fiduciary?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel